Preparation, Optimization and In vitro Evaluation of Glipizide Nanoparticles Integrated with Eudragit RS-100

Author(s): P. Saharan, K. Bahmani*, S.P. Saharan.

Journal Name: Pharmaceutical Nanotechnology

Volume 7 , Issue 1 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Solubility is an important criterion for drug efficacy, independent of the route of administration. It also poses a major challenge for pharmaceutical industries, which are developing new pharmaceutical products, since 40% of the active substances being identified are either insoluble or poorly soluble in aqueous media.

Objective: The objective of this study was to develop nanoformulation of glipizide drugloaded nanoparticles providing controlled release formulation.

Method: Nanoparticles were prepared by the solvent evaporation method. Eudragit RS100, a nonbiodegradable polymer with varying ratios was used for making the formulation. The effect of key formulation variables on the particle size and entrapment efficiency and drug loading of nanoparticles were studied by using factorial design.

Results: DSC thermograms indicate that glipizide was dispersed in an amorphous state in the polymer. TEM study indicates that the nanoparticles were in spherical shape. The mean diameter was dependent on the presence of the amount of Eudragit RS100 and viscosity of the organic phase. The in vitro study showed that the cumulative drug release was from 69.52-81.44 % in 10 hrs at pH 6.8 in phosphate buffer respectively.

Conclusion: The developed NPs could reduce dose frequency, decrease side effects, and improve patient compliance. Using factorial design, maximum entrapment efficiency with minimum particle size could be achieved with a few experiments.

Keywords: Characterization, Eudragit RS-100, glipizide, optimization, solvent evaporation, nanoparticles.

[1]
Dora CP, Singh SK, Kumar S, Datusalia AK, Deep A. Development and characterization of nanoparticles of glibenclamide by solvent displacement method. Acta Pol Pharm Drug Res 2010; 67(3): 283-90.
[2]
Baily CJ. Potential new treatments for type two diabetes. Tips 2000; 21: 259-65.
[3]
Harlay CR. Glipizide GRTS has advantages over other second generation sulfonylurea. Clin Drug Investig 2002; 22: 575-84.
[4]
Hesieh SH, Lin JD, Chang HY, Ho Ch, Liou MJ. Sustained release versus immediate release glipizide for the treatment of diabetes mellitus in Chinese patients: a randomized, double blind, double dummy, parallel group, 12 week clinical study. Clin Ther 2006; 28: 1318-26.
[5]
Venkateswarlu K, and Shanthi A. Formulation and evaluation of sustained release glipizide matrix. IOSR J Pharm Biol Sci 2012; 2(5): 17-23.
[6]
Muthu MS. Nanoparticles based on PLGA and its copolymer: an overview. Asian J Pharm 2009; 3: 266-73.
[7]
Price J. Handbook of Pharmaceutical Excipients. The Pharmaceutical Press: London 2003; pp. 1-917.
[8]
Singh S. Neelam, Arora S, Singla YP. An overview of multifaceted significance of eudragit polymers in drug delivery systems. Asian J Pharm Clin Res 2015; 8(5): 1-6.
[9]
Chowdary KPR, Srinivasa YR. Design and in vitro evaluation of mucoadhesive controlled release oral tablet of glipizide. Indian J Pharm 2003; 65: 592-9.
[10]
Singh B, Bhatowa R, Tripathi CB, Kapil R. Developing micro-/nanoparticulate drug delivery systems using “design of experiments”. Int J Pharm Investig 2011; 1(2): 75-81.
[11]
Verma RK, Garg S. Development and evaluation of osmotically controlled oral delivery system of glipizide. Eur J Pharm Biopharm 2004; 57: 513-25.
[12]
Myers RH, Montgomery DC. Response surface methodology: process and product optimization using designed experiments. New York: John Wiley & Sons 2002.
[13]
Thombre AG, Denoto AR, Gibbes DC. Delivery of glipizide from asymmetric membrane capsules using encapsulated excepients. J Control Release 1999; 60: 333-41.
[14]
Florence AT. Issues in oral nanoparticle drug carrier uptake and targeting. J Drug Target 2004; 12: 65-70.
[15]
Khafagy ES, Morishita M, Onuki Y, Takayama K. Current challenges in non-invasive insulin delivery systems: a comparative review. Adv Drug Deliv Rev 2007; 59(15): 1521-46.
[16]
Patel JK, Patel RP, Amin AF, Patel MM. Formulation and evaluation of mucoadhesive glipizide microspheres. AAPS PharmSciTech 2005; 6: 49-55.
[17]
Harivardhan LR, Murthy RSR. Influence of polymerization technique and experimental variables on the particle properties and release kinetics of methotrexate from poly (butylcyanoacrylate) nanoparticles. Acta Pharm 2004; 54: 103-18.
[18]
Florence A, Hillery A, Hussain N, Jani P. Nanoparticles as carriers for oral peptide absorption: studies on particle uptake and fate. J Control Release 1995; 36(1-2): 39-46.
[19]
Sonavane GS, Devarajan PV. Preparation of alginate nanoparticles using Eudragit E100 as a new complexing agent: development, in-vitro, and in-vivo evaluation. J Biomed Nanotechnol 2007; 3: 160-9.
[20]
Zengshuan MA, Yeoh HH, Lim LY. Formulation pH modulates of insulin with chitosan nanoparticles. J Pharm Sci 2002; 91: 1396-404.
[21]
Crowley MM, Schroeder B, Fredersdrof A, et al. Physicochemical properties and mechanism of drug release from ethylcellulose matrix tablets prepared by direct compression and hot-melt extrusion. Int J Pharm 2004; 269: 509-22.
[22]
Ehtezazi T, Washington C, Melia CD. First order release rate from porous PLA microspheres with limited exit on the exterior surface. J Control Release 2000; 66: 27-38.
[23]
Akl MA, Kartal-Hodzic A, Oksanen T, et al. Factorial design formulation optimization and in vitro characterization of curcumin-loaded PLGA nanoparticles for colon delivery. J Drug Deliv Sci Technol 2016; 32: 10-20.
[24]
Lokhande A, Mishra S, Kulkarni R, Naik J. Formulation and evaluation of glipizide loaded nanoparticles. J Pharm Pharm Sci 2013; 5: 147-51.
[25]
Nayak AK, Pal D, Santra K. Ispaghula mucilage-gellan mucoadhesive beads of metformin HCl: development by response surface methodology. Carbohydr Polym 2014; 107: 41-50.
[26]
Malakar J, Nayak AK, Goswami S. Use of response surface methodology in the formulation and optimization of bisoprolol fumarate matrix tablets for sustained drug release. ISRN Pharmacol 2012; 2012: 1-10.
[27]
Nayak AK, Pal D, Santra K. Plantago ovata F. Mucilage-alginate mucoadhesive beads for controlled release of glibenclamide: development, optimization, and in vitro-in vivo evaluation. J Pharm 2013; 2013: 1-13.
[28]
Shid RL, Dhole SN, Kulkarni N, Shid SL. Formulation and evaluation of nanosuspension delivery system for simvastatin. Int J Pharm Sci Nanotechnol 2014; 7: 2459-76.
[29]
Naha PC, Byrne HJ, Panda AK. Role of polymeric excipients on controlled release profile of Glipizide from PLGA and Eudragit RS 100 Nanoparticles. J Nanopharm Drug Deliv 2013; 1(1): 74-81.
[30]
Verma S, Singh SK, Verma PR. Fabrication of lipidic nanocarriers of loratadine for facilitated intestinal permeation using multivariate design approach. Drug Dev Ind Pharm 2016; 42(2): 288-306.
[31]
Bera K, Khanam J, Mohanraj KP, Mazumder B. Design and evaluation of mucoadhesive beads of glipizide as a controlled release drug delivery system. J Microencapsul 2014; 31(3): 220-9.
[32]
Rao ME, Swain S, Patra CN, Mund SP. Formulation Design, Optimization and Characterization of Eprosartan Mesylate Nanoparticles. Nanosci Nanotechnol Asia 2018; 8(1): 130-43.
[33]
Petkar KC, Chavhan S, Kunda N, et al. Development of novel octanoyl chitosan nanoparticles for improved rifampicin pulmonary delivery: optimization by factorial design. AAPS PharmSciTech 2018; 31: 1-5.
[34]
Verma U, Naik JB, Deshmukh R, Mishra S. Development of biodegradable glimepiride loaded chitosan nano particles: a factorial design approach. Curr Environ Eng 2018; 5(1): 68-77.
[35]
Jain S, Jain A, Bhargav S. Formulation and evaluation of embelin loaded pectin nanoparticles for the treatment of diabetes. Pancreatology 2018; 18(4): S39.
[36]
Reis CP, Neufeld RJ, Veiga F. Preparation of drugloaded polymeric nanoparticles. In Nanomed Cancer2017; 2(1): 8-2.
[37]
Landry F, Bazile D, Spenlehauer G, Veillard M, Kreuter J. Influence of the coating agents on the degradation of poly (D,L lactic acid) nanoparticles in model digestive fluids. STP Pharma Sci 1996; 6(3): 195-202.
[38]
Parikh R, Parikh J, Dubey R, Soni H, Kapadia K. Poly (D,L-lactide-coglycolide) microspheres containing 5-fluorouracil: optimization of process parameters. AAPS PharmSciTech 2003; 4(2): E13.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 7
ISSUE: 1
Year: 2019
Page: [72 - 85]
Pages: 14
DOI: 10.2174/2211738507666190319124513

Article Metrics

PDF: 21
HTML: 6